303 related articles for article (PubMed ID: 35358307)
21. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.
Vollenberg R; Tepasse PR; Lorentzen E; Nowacki TM
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629116
[TBL] [Abstract][Full Text] [Related]
22. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
Zacharopoulou E; Orfanoudaki E; Tzouvala M; Tribonias G; Kokkotis G; Kitsou V; Almpani F; Christidou A; Viazis N; Mantzaris GJ; Tsafaridou M; Karmiris K; Theodoropoulou A; Papathanasiou E; Zampeli E; Michopoulos S; Tigkas S; Michalopoulos G; Laoudi E; Karatzas P; Mylonas I; Kyriakos N; Liatsos C; Kafetzi T; Theocharis G; Taka S; Panagiotopoulou K; Koutroubakis IE; Bamias G
Inflamm Bowel Dis; 2023 Feb; 29(2):228-237. PubMed ID: 35394529
[TBL] [Abstract][Full Text] [Related]
23. Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring.
Crespo M; Barrilado-Jackson A; Padilla E; Eguía J; Echeverria-Esnal D; Cao H; Faura A; Folgueiras M; Solà-Porta E; Pascual S; Barbosa F; Hurtado S; Ribera L; Río-No L; Pérez-Sáez MJ; Redondo-Pachón D; Pascual J
Am J Transplant; 2022 Mar; 22(3):786-800. PubMed ID: 34551187
[TBL] [Abstract][Full Text] [Related]
24. Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation.
Azamor T; Horbach IS; Brito E Cunha D; Melgaço JG; Silva AMVD; Tubarão LN; Azevedo AS; Santos RT; Alves NDS; Machado TL; Silva J; Souza AF; Bayma C; Rocha VP; Frederico ABT; Dias BM; Setatino BP; Denani CB; Campos SPDC; Schwarcz WD; Sucupira MV; Mendes EP; Silva EDD; Barbosa de Lima SM; Ano Bom APD; Missailidis S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146723
[TBL] [Abstract][Full Text] [Related]
25. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
[TBL] [Abstract][Full Text] [Related]
26. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
[TBL] [Abstract][Full Text] [Related]
27. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
28. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
29. A Pilot Study for the Evaluation of an Interferon Gamma Release Assay (IGRA) To Measure T-Cell Immune Responses after SARS-CoV-2 Infection or Vaccination in a Unique Cloistered Cohort.
Barreiro P; Sanz JC; San Román J; Pérez-Abeledo M; Carretero M; Megías G; Viñuela-Prieto JM; Ramos B; Canora J; Martínez-Peromingo FJ; Barba R; Zapatero A; Candel FJ
J Clin Microbiol; 2022 Mar; 60(3):e0219921. PubMed ID: 35020419
[TBL] [Abstract][Full Text] [Related]
30. T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease.
Reuken PA; Andreas N; Grunert PC; Glöckner S; Kamradt T; Stallmach A
J Crohns Colitis; 2022 Feb; 16(2):251-258. PubMed ID: 34379729
[TBL] [Abstract][Full Text] [Related]
31. Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response.
Renaudineau Y; Abravanel F; Izopet J; Bost C; Treiner E; Congy N; Blancher A
Clin Immunol; 2022 Apr; 237():108979. PubMed ID: 35301104
[TBL] [Abstract][Full Text] [Related]
32. Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease.
Kastl AJ; Weaver KN; Zhang X; Strople JA; Adler J; Dubinsky MC; Bousvaros A; Watkins R; Dai X; Chen W; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda EA; Farraye FA; Chun KY; Zikry M; Fernando M; Bastidas M; Hernandez CG; Craig RG; Boccieri ME; Firestine A; Long MD; Kappelman MD
Am J Gastroenterol; 2023 Jan; 118(1):129-137. PubMed ID: 36114773
[TBL] [Abstract][Full Text] [Related]
33. Interferon-gamma release assays outcomes in healthy subjects following BNT162b2 mRNA COVID-19 vaccination.
Kurteva E; Vasilev G; Tumangelova-Yuzeir K; Ivanova I; Ivanova-Todorova E; Velikova T; Kyurkchiev D
Rheumatol Int; 2022 Mar; 42(3):449-456. PubMed ID: 35059799
[TBL] [Abstract][Full Text] [Related]
34. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.
Einarsdottir S; Martner A; Waldenström J; Nicklasson M; Ringlander J; Arabpour M; Törnell A; Wiktorin HG; Nilsson S; Bittar R; Nilsson M; Lisak M; Veje M; Friman V; Al-Dury S; Bergström T; Ljungman P; Brune M; Hellstrand K; Lagging M
Blood Adv; 2022 May; 6(9):2723-2730. PubMed ID: 35286374
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
36. Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease.
Stercel V; Lóczi L; Kadenczki O; Nemes É; Nagy B; Hodossy-Takács R; Szabó AÁ; Fagyas M; Kappelmayer J; Szabó T; Bagoly Z
Front Immunol; 2023; 14():1257072. PubMed ID: 37965328
[TBL] [Abstract][Full Text] [Related]
37. Easy approach to detect cell immunity to COVID vaccines in common variable immunodeficiency patients.
Barrios Y; Franco A; Alava-Cruz C; Cuesta-Martin R; Camara C; Matheu V
Allergol Immunopathol (Madr); 2022; 50(3):101-105. PubMed ID: 35527662
[TBL] [Abstract][Full Text] [Related]
38. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
[TBL] [Abstract][Full Text] [Related]
39. Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19.
Kirchner T; Heinrich S; Bonifacius A; Engel B; Ruhl L; Pink I; Thomas N; Martens J; Hoeper MM; Blasczyk R; Wedemeyer H; Jaeckel E; Li Y; Falk CS; Eiz-Vesper B; Taubert R
PLoS One; 2022; 17(11):e0276929. PubMed ID: 36322587
[TBL] [Abstract][Full Text] [Related]
40. Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers.
Smit W; Thijsen S; van der Kieft R; van Tol S; Reimerink J; Reusken C; Rümke L; Bossink A; Limonard G; Heron M
Pathog Dis; 2022 Oct; 80(1):. PubMed ID: 36089571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
